Just 6% of the Asian doctors said they felt confident using biosimilars in clinical practice. A survey of European doctors found a similar confidence level in 2013, but that level had climbed to 28.8% by 2015.
Compared with their European colleagues, Asian gastroenterologists have less confidence in biosimilars, according to survey results reported in the Korean Journal of Gastroenterology.
The report discussed results of a 17-question survey sent to members of the Asian Organization of Crohn’s and Colitis (AOCC). Initially, 320 members were randomly selected to participate, and 151 doctors from 8 Asian countries responded. The survey was done by email from February 24, 2017, to March 26, 2017. Nearly all respondents were gastroenterologists (96.6%), and 77.5% had cared for patients with inflammatory bowel disease (IBD) for at least 5 years.
Notably, just 6% of the Asian doctors said they felt confident using biosimilars in clinical practice. The finding was comparable with a 2013 survey of members of the European Crohn’s and Colitis Organization (ECCO), which found just 5% felt confident using biosimilars in practice; by 2015, however, that share had increased to 28.8%.
Other survey results showed:
The 2015 ECCO survey had found that European doctors were more impressed with the cost savings and less concerned about a different immunogenicity than the Asian respondents. The ECCO results found:
In the AOCC survey, 86.7% disagreed that pharmacists should automatically substitute biosimilars for originators, which was similar to the ECCO findings (85% in 2013 and 89.8% in 2015). When asked when substitution was appropriate, 62.3% of Korean physicians disagreed with automatic substitution in any case, compared with 38.8% of Japanese doctors and 11.8% of Chinese doctors.
The authors note that the first infliximab biosimilar, CT-P13 (Remsima, Celltrion) was manufactured by a Korean biopharmaceutical company and licensed in Korea in 2012. By 2017, 74.2% of the participants were from countries where this biosimilar was available, and the doctors were generally well-informed about what biosimilars are.
The share of physicians who prescribed biosimilars for more than 2 years was 41.5% in Korea, 20.6% in China, and less than 5% in other Asian countries. The authors noted that there is a relatively small price difference between biosimilars and originators in Asian markets compared with ECCO countries, which could explain the lack of uptake in some countries.
“Compared to ECCO members in 2015, Asian gastroenterologists had more concerns and less confidence about the use of biosimilars in clinical practice,” the authors concluded. “Thus, IBD-specific data on a comparison of the efficacy, safety, and immunogenicity in Asian patients will be needed.”
Reference
Park SK, Moon W, Kim ES, Park SH, Park D. Knowledge and viewpoints on biosimilar monoclonal antibodies among Asian physicians: comparison with European physicians. Korean J Gastroentrol. 2010;74(6):333-340.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.